Gujarat Terce Laboratories
Healthcare
524314 BSE
₹44.15
Close ·
- P/E
- 15.94
Close 4 Nov 2026 ₹44.15 0.00 0.00% 1Y
Start ₹44.15
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 39.20%
- Debt to Equity
- 0.13
- EPS (TTM)
- ₹2.77
- Book Value
- ₹12.49
- Market Cap
- —
- P/E (TTM)
- 15.94
- P/B
- 3.53
- ROE
- 30.20%
- Dividend Yield
- 0.00%
- EBITDA
- ₹4.10 Cr
- 52W High
- ₹50.00
- 52W Low
- ₹29.00
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
51 Average
Data confidence 100/100
Category scores
- Quality
- 47
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 53
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 28
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 48
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 83
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
1- Company has a low return on equity of 7.77% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 4 | 12 |
| Oscillators | Bearish | 3 | 4 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Bearish
3
Neutral
4
Bullish
2
Overall
Strong Bullish
Bearish
3
Neutral
4
Bullish
12
Moving Averages
Strong Bullish
Bearish
0
Neutral
0
Bullish
10
Key readings
- RSI (14)
- 60.49
- Neutral
- MACD (12,26,9)
- 1.44
- Bullish
- SMA (50)
- 38.72
- Bullish
- SMA (200)
- 37.80
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +6.62% |
|---|---|
| 5Y | +13.52% |
| 3Y | +0.49% |
| 1Y | −5.44% |
| TTM | −7.18% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | Turned to profit |
| 3Y | Turned to profit |
| 1Y | Turned to profit |
| TTM | Turned to profit |
Operating cash flow
| 10Y | +26.73% |
|---|---|
| 5Y | Turned positive |
| 3Y | +284.85% |
| 1Y | −44.12% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +7.28 pp |
|---|---|
| 5Y | +18.21 pp |
| 3Y | +12.54 pp |
| 1Y | +0.17 pp |
| TTM | −0.50 pp |
Revenue by year
| Mar 2017 | ₹25.29 Cr |
|---|---|
| Mar 2018 | ₹29.01 Cr |
| Mar 2019 | ₹31.03 Cr |
| Mar 2020 | ₹37.54 Cr |
| Mar 2021 | ₹25.18 Cr |
| Mar 2022 | ₹40.13 Cr |
| Mar 2023 | ₹46.78 Cr |
| Mar 2024 | ₹47.92 Cr |
| Mar 2025 | ₹50.20 Cr |
| Mar 2026 | ₹47.47 Cr |
Net profit by year
| Mar 2017 | −₹0.01 Cr |
|---|---|
| Mar 2018 | ₹0.27 Cr |
| Mar 2019 | ₹0.43 Cr |
| Mar 2020 | ₹0.28 Cr |
| Mar 2021 | −₹2.52 Cr |
| Mar 2022 | ₹0.87 Cr |
| Mar 2023 | −₹1.67 Cr |
| Mar 2024 | ₹0.24 Cr |
| Mar 2025 | −₹0.98 Cr |
| Mar 2026 | ₹2.20 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.72 | 12.03 | 13.02 | 12.21 | 11.89 | 13.3 | 12.68 | 12.32 | 10.85 | 12.93 | 12.29 | 11.4 | 9 |
| Expenses | 11.85 | 11.48 | 12.18 | 11.2 | 11.81 | 11.64 | 11.6 | 11.27 | 10.86 | 11.03 | 11.16 | 10.66 | 9.49 |
| Operating Profit | −1.13 | 0.55 | 0.84 | 1.01 | 0.08 | 1.66 | 1.08 | 1.05 | −0.01 | 1.9 | 1.13 | 0.74 | −0.49 |
| OPM % | −10.54% | 4.57% | 6.45% | 8.27% | 0.67% | 12.48% | 8.52% | 8.52% | −0.09% | 14.69% | 9.19% | 6.49% | −5.44% |
| Other Income | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | 0.09 | 0.09 | 0.05 | 0.13 | −0.37 | 0.48 |
| Interest | 0.17 | 0.2 | 0.16 | 0.15 | 0.13 | 0.13 | 0.08 | 0.07 | 0.05 | 0.07 | 0.04 | 0.03 | 0.03 |
| Depreciation | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.13 | 0.11 |
| PBT | −1.31 | 0.34 | 0.67 | 0.85 | −0.07 | 1.52 | 0.97 | 0.97 | −0.07 | 1.78 | 1.12 | 0.21 | −0.15 |
| Tax % | 0% | 0% | 0% | 35.29% | 14.29% | 1.97% | −3.09% | 449.48% | −42.86% | 21.35% | 33.04% | 47.62% | 20% |
| Net Profit | −1.31 | 0.33 | 0.67 | 0.54 | −0.08 | 1.48 | 1.01 | −3.39 | −0.04 | 1.4 | 0.76 | 0.1 | −0.18 |
| EPS (₹) | −1.77 | 0.44 | 0.9 | 0.73 | −0.11 | 1.99 | 1.36 | −4.57 | −0.05 | 1.89 | 0.98 | 0.13 | −0.23 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.48 | 25 | 25.29 | 29.01 | 31.03 | 37.54 | 25.18 | 40.13 | 46.78 | 47.92 | 50.2 | 47.47 | 45.62 |
| Expenses | 25.7 | 24.84 | 25.21 | 28.68 | 30.54 | 36.86 | 27.77 | 39.02 | 48.94 | 46.65 | 46.31 | 43.71 | 42.34 |
| Operating Profit | 0.78 | 0.16 | 0.08 | 0.33 | 0.49 | 0.68 | −2.59 | 1.11 | −2.16 | 1.27 | 3.89 | 3.76 | 3.28 |
| OPM % | 2.95% | 0.64% | 0.32% | 1.14% | 1.58% | 1.81% | −10.29% | 2.77% | −4.62% | 2.65% | 7.75% | 7.92% | 7.19% |
| Other Income | 0.08 | 0.19 | 0.44 | 0.41 | 0.32 | 0.29 | 0.62 | 0.31 | 0.35 | 0.32 | 0.31 | −0.12 | 0.29 |
| Interest | 0.41 | 0.38 | 0.31 | 0.23 | 0.25 | 0.29 | 0.39 | 0.4 | 0.72 | 0.68 | 0.42 | 0.18 | 0.17 |
| Depreciation | 0.16 | 0.19 | 0.19 | 0.19 | 0.21 | 0.24 | 0.18 | 0.28 | 0.36 | 0.37 | 0.38 | 0.42 | 0.44 |
| PBT | 0.29 | −0.22 | 0.02 | 0.32 | 0.35 | 0.44 | −2.54 | 0.74 | −2.89 | 0.54 | 3.4 | 3.04 | 2.96 |
| Tax % | 72.41% | 209.09% | 150% | 15.62% | −25.71% | 36.36% | −0.39% | −17.57% | −42.21% | 55.56% | 128.53% | 27.3% | — |
| Net Profit | 0.09 | −0.67 | −0.01 | 0.27 | 0.43 | 0.28 | −2.52 | 0.87 | −1.67 | 0.24 | −0.98 | 2.2 | 2.08 |
| EPS (₹) | 0.12 | −0.9 | −0.01 | 0.36 | 0.58 | 0.38 | −3.4 | 1.17 | −2.25 | 0.32 | −1.32 | 2.82 | 2.77 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.79 |
| Reserves | 3.61 | 2.94 | 2.64 | 2.98 | 3.41 | 3.69 | 0.24 | 1.11 | −0.56 | −0.31 | −0.94 | 1.94 |
| Borrowings | 8.21 | 7.13 | 7 | 0.37 | 0.68 | 2.6 | 4.74 | 6.67 | 7.27 | 3.87 | 0.94 | 1.3 |
| Other Liabilities | 7.06 | 6.98 | 6.59 | 8.69 | 7.94 | 8.8 | 9.47 | 12.19 | 14.39 | 12.29 | 15.41 | 13.52 |
| Total Liabilities | 26.3 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.55 |
| Fixed Assets | 6.48 | 6.34 | 6.17 | 1.88 | 2.06 | 2.29 | 2.45 | 4.29 | 3.99 | 3.69 | 3.65 | 3.25 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.3 | 0.3 | 0.24 | 0.27 | 0.29 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.52 | 1.35 |
| Other Assets | 19.52 | 17.83 | 17.24 | 17.31 | 17.1 | 19.95 | 19.15 | 22.83 | 24.26 | 19.31 | 18.66 | 19.95 |
| Total Assets | 26.3 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.55 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1.38 | 0.16 | 0.24 | 4.58 | −0.61 | −1.59 | −0.16 | −0.44 | 0.03 | 2.6 | 3.06 | 1.71 |
| Investing | 0.08 | −0.13 | 0.18 | 1.11 | −0.13 | −0.27 | −0.42 | −0.87 | 0.62 | −0.46 | 0.46 | −0.11 |
| Financing | −0.73 | −1.43 | −0.36 | −5.39 | 0.2 | 1.72 | 1.83 | 1.53 | −0.12 | −4.08 | −2.83 | 0.47 |
| Net Cash Flow | 0.73 | −1.39 | 0.06 | 0.29 | −0.55 | −0.14 | 1.24 | 0.22 | 0.52 | −1.94 | 0.69 | 2.08 |
| Free Cash Flow | 0.92 | 0.1 | 0.23 | 4.45 | −1.01 | −2.07 | −0.66 | −2.55 | −0.03 | 2.53 | 3.41 | 1.69 |
| CFO/OP | 191 | 406 | 688 | 1,418 | −98 | −219 | 0 | −31 | −3 | 205 | 81 | 45 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 127 | 124 | 114 | 57.62 | 53.29 | 68.16 | 74.94 | 49.75 | 62.34 | 43.11 | 36.86 | 37.45 |
| Inventory Days | 143 | 163 | 150 | 126 | 115 | 90 | 137 | 154 | 83.56 | 81.09 | 70.81 | 79.43 |
| Days Payable | 88.41 | 92.3 | 59.7 | 111 | 85.26 | 83.44 | 104 | 96.22 | 110 | 97.39 | 69.65 | 33.65 |
| Cash Conversion Cycle | 181 | 194 | 205 | 73.29 | 82.72 | 74.72 | 107 | 107 | 35.56 | 26.81 | 38.02 | 83.23 |
| Working Capital Days | 97.04 | 111 | 86.74 | 20.89 | 27.88 | 25.18 | −14.06 | 6.82 | −20.21 | −7.69 | −13.89 | −5.77 |
| ROCE % | 3.39% | 0.87% | 1.91% | 2.95% | 5.39% | 5.79% | −15.09% | 8.26% | −14.8% | 9.72% | 41.41% | 39.24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Gujarat Terce Laboratories insights
63 extracted metrics across FY10–FY27.
Documents
- General announcements 9 Oct 2026
Frequently Asked Questions about Gujarat Terce Laboratories
What does Gujarat Terce Laboratories Ltd do?
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
Where is Gujarat Terce Laboratories Ltd (GUJTERC) listed?
Gujarat Terce Laboratories Ltd trades under code 524314 on the BSE.
Which sector does Gujarat Terce Laboratories Ltd belong to?
Gujarat Terce Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd trades at a PE ratio of 15.94 as of 4 Nov 2026, on earnings per share of ₹2.77, against a book value of ₹12.49 per share.
What is the 52-week high and low of Gujarat Terce Laboratories Ltd?
Over the last 52 weeks Gujarat Terce Laboratories Ltd has traded between ₹29 and ₹50 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd reported a return on equity of 30.20%. Its debt-to-equity ratio is 0.13.
Company Information
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
Website gujaratterce.in
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524314.md for Gujarat Terce Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.